Genmab AS

Healthcare · Biotechnology

38.50$ +10.7% vs. previous close Closing price · As of: Oct 5, 2026

Statements

Income Statement

Genmab AS (GMAB) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 1,155 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement GMAB
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	LTM
Revenue	365	927	251	773	323	1,018	681	510	599	1,236	591	774	1,040	2,961	892	5,451	1,724	2,044	1,581	1,972	2,310	2,619	2,119	3,162	4,087	5,137	2,834	4,169	4,712	4,678	603	779	5,540	6,441	105	925	1,022	1,055	899	1,155	4,131
Cost of Revenue	–	–	–	–	–	–	–	0.0	0.0	0.0	0.0	0.0	0.0	0.0	–	–	–	–	–	–	–	–	–	–	0.0	–	0.0	21	79	126	27	28	273	337	6.2	57	58	81	65	84	288
Gross Profit	365	927	251	773	323	1,018	681	510	599	1,236	591	774	1,040	2,961	892	5,451	1,724	2,044	1,581	1,972	2,310	2,619	2,119	3,162	4,087	5,137	2,834	4,148	4,633	4,552	576	751	5,267	6,104	99	868	964	974	834	1,071	3,843
Research & Development	151	196	170	202	228	275	313	319	343	456	546	563	608	669	715	775	721	926	848	921	1,114	1,298	1,153	1,282	1,486	1,641	1,741	1,853	2,088	1,948	335	361	2,283	2,664	53	364	357	524	442	459	1,782
Selling, General & Administrative	27	24	35	35	37	40	44	56	55	58	71	73	81	117	106	179	145	231	201	264	306	512	452	633	670	921	676	848	839	934	857	894	865	1,249	126	144	148	208	166	205	727
Total Operating Expenses	178	220	205	237	265	314	357	375	398	515	617	637	689	785	821	954	866	1,157	1,049	1,185	1,420	1,810	1,605	1,915	2,156	2,562	2,417	2,680	2,948	2,882	460	515	3,165	3,944	71	508	505	732	608	664	2,509
Operating Income	187	708	46	536	58	703	324	135	200	721	-26	137	351	2,176	71	4,497	858	887	532	787	890	809	514	1,247	1,931	2,575	417	1,468	1,685	1,670	116	236	2,102	2,160	28	360	459	242	226	407	1,334
Interest Expense	–	0.2	0.1	145	66	2.2	0.1	0.1	0.0	0.1	2.0	60	8.0	1.3	2.0	211	720	3.0	3.0	430	4.0	3.0	4.0	6.0	6.0	5.0	6.0	7.0	8.0	6.0	4.0	19	18	54	0.7	9.0	3.0	44	112	110	269
Pre-Tax Income	189	785	20	391	-7.2	660	256	335	231	790	94	111	699	1,955	354	4,328	671	551	1,424	422	1,171	966	612	2,489	3,272	572	266	1,694	2,670	926	249	307	1,719	3,602	36	423	482	55	74	295	906
Income Tax Expense	–	-57	4.4	84	-1.5	-126	57	75	51	-43	22	26	162	483	85	950	141	-30	328	116	281	250	147	598	690	58	56	359	566	286	57	104	453	-243	7.2	87	81	24	21	-8.0	118
Net Income	189	841	16	307	-5.7	786	199	261	179	834	72	85	537	1,472	269	3,378	530	581	1,096	306	890	716	465	1,891	2,582	514	210	1,335	2,104	640	192	203	1,266	3,845	29	336	401	31	53	303	788
EBITDA	195	785	56	536	69	737	324	147	212	743	-4.0	159	373	1,998	391	4,532	1,426	612	1,485	910	1,233	1,031	678	2,557	3,340	2,667	326	1,755	2,764	992	266	324	2,204	2,355	39	448	503	99	187	431	1,219

LTM = last twelve months (sum of the four most recent quarters).

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Income Statement

Cookie settings